Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharmaceuticals has signed a letter of intent with Yiaco Medical of Kuwait, for the commercialization of Davanat for the treatment of colorectal and biliary cancer.
Subscribe to our email newsletter
Yiaco Medical serves 18 countries and represents 80 healthcare companies in the Middle East and North Africa with a population of more than 400 million.
Hamed Hamadah, chairman and managing director, Yiaco Medical, said: “Through this collaboration with Pro-Pharmaceuticals, we have now gained access to a promising cancer therapy that potentially allows us to address an area of high medical importance where current therapies are clearly inadequate.”